Hyphens Pharma International Ltd logo

1J5

SGX

Hyphens Pharma International Ltd

Health CareSingapore

Company Overview

Ticker: 1J5
Exchange: SGX
Sector: Health Care
Industry: -
Market Cap: -
FY End: December
Employees: -

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products in ASEAN countries. This segment focuses on various therapeutic areas, such as dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics. Its Proprietary Brands segment develops, markets, and sells dermatological products comprising Ceradan, TDF, and CG210; health supplements under the Ocean Health brand covering areas, such as heart, joint, physical, cognitive, eye, and health; and pharmaceuticals. The Digital Platform and E-Pharmacy segment operates a digital platform that services procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies primarily in Singapore. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.

Leadership Team

LS
Lim See Wah

Chairman and Chief Executive Officer

YM
Yann Marche

Key Management Personnel

DL
David Lim

Key Management Personnel

JY
Jason Yeo

Key Management Personnel

ZY
Zhang Yufan (Flora)

Key Management Personnel

TK
Tan Kia King

Non-Executive Director

HW
Heng Wee Koon

Independent Director, Chairman of Audit Committee

NE
Ng Eng Leng

Independent Director, Chairman of Remuneration Committee

AL
Audrey Liow

Independent Director

CK
Chan Kiat

Independent Director

TK
Tan Kia King

Director

LS
Lim See Wah

Director

HW
Heng Wee Koon

Independent Director, Audit Committee Chairman

NE
Ng Eng Leng

Independent Director, Audit Committee Member

TS
Tan Seok Hoong @ Mrs Audrey Liow

Independent Director, Audit Committee Member

CK
Chan Kiat

Independent Director, Audit Committee Member

LC
Leonard Chiu

Chief Technology Officer

SW
See Wah Lim

Executive Chairman & CEO

YJ
Yeo Jason

Managing Director of Pan-Malayan Pharmaceuticals & Novem Healthcare

TL
Tay Lay Keow

Head of HR & Admin

YZ
Yufan Zhang

Chief Financial Officer

SA
Stella Ang

Head of Regulatory Affairs

YA
Yann Alain Marche

Chief Operating Officer

AF
Ang Francis

Country Head of Malaysia

JS
Josiephine Sac-Mantoya

Country Head of Philippines

JI
Jamal Iflizar

Country Head of Indonesia

Recent Announcements

No announcements yet.

Price Chart

Insufficient price data

Key Metrics

P/E Ratio15.75
P/B Ratio1.39
EV/EBITDA4.83
Dividend Yield4.8%
ROE8.3%
ROA6.9%
Net Margin3.3%
Debt/Equity0.13
Net Debt/EBITDA-1.02
FCF Yield-

Governance Score

-

SGX Code of Corporate Governance

StocksSG provides data for informational purposes only. This is not financial advice. Information may contain errors or be outdated. Always verify data independently and consult a licensed financial adviser before making investment decisions.

Data sources · Full disclaimer